Business Context and Reporting Period
This Form 8-K filing by CRISPR Therapeutics AG, dated October 2, 2017, reports a significant change in executive leadership. The Company, incorporated in Switzerland, announced the resignation of Rodger Novak, M.D., as Chief Executive Officer (CEO), effective December 1, 2017. Samarth Kulkarni, Ph.D., currently President and Chief Business Officer, will succeed Dr. Novak as CEO on the same date. Dr. Novak will transition to the role of President and remain on the Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on executive compensation and employment terms.
- CEO Base Salary (Pre-Transition): $415,000 annually.
- CEO Base Salary (Post-Transition): $500,000 annually, subject to yearly adjustments.
- Performance Bonus (Pre-Transition): Minimum 45% of annual salary.
- Performance Bonus (Post-Transition): Minimum 50% of annual salary.
- Equity Grant (Time-Based): Option to purchase 260,000 common shares vesting over 48 months; 26,667 restricted stock units vesting over 16 quarters.
- Equity Grant (Performance-Based): Option to purchase 150,000 common shares contingent on stock price milestones of $40.00 and $50.00 per share.
Material Changes Versus Prior Period
The primary material change is the amendment of Dr. Kulkarni's employment agreement to reflect his new role as CEO. Key changes include:
- Base salary increase from $415,000 to $500,000 effective December 1, 2017.
- Increase in minimum annual performance bonus eligibility from 45% to 50% of salary.
- Grant of new equity awards (260,000 options, 26,667 RSUs, and 150,000 performance-based options) conditioned on continued employment and specific stock price targets.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, market outlook, or general risk factors. However, it outlines specific contingencies regarding executive compensation:
- Performance Milestones: Vesting of the 150,000 performance-based options is contingent on the Company's Average Stock Price exceeding $40.00 (for 50% of the grant) and $50.00 (for the remaining 50%) prior to the third anniversary of the grant.
- Termination Provisions: In the event of an "Involuntary Departure," unvested earned options will vest in full. In the event of a "Sale Event," unvested options may become fully vested or eligible to be earned based on stock price at consummation.
- Forfeiture: Any portion of the performance-based grant not earned by the vesting date will be cancelled and forfeited.
Investor Verification Checklist
- Verify the exact vesting schedule and cliff dates for the 260,000 time-based options and 26,667 RSUs granted to Dr. Kulkarni.
- Confirm the definition of "Average Stock Price" used to determine vesting of the 150,000 performance-based options.
- Review the full text of the Second Amended and Restated Employment Agreement (Exhibit 10.1) for detailed definitions of "Involuntary Departure" and "Sale Event."
- Monitor the Company's stock price relative to the $40.00 and $50.00 thresholds to assess potential future dilution from the performance-based grant.